Navigation Links
ALS Therapy Development Institute and Anida Pharma Partner to Investigate Potential Treatments for ALS
Date:9/10/2013

erapeutics, including a pipeline of dozens of small molecules, protein biologics, gene therapies and cell-based constructs. The world's first nonprofit biotech institute, ALS TDI employs 30 professional scientists, evaluates dozens of potential therapeutics each year and is currently executing a Phase IIA clinical trial of TDI-132 (Novartis' Gilenya®) in ALS patients.  Built by and for patients, the Cambridge, Massachusetts-based research institute collaborates with leaders in both academia and industry to accelerate ALS therapeutic development, including Biogen Idec, UCB, the Gladstone Institutes, MDA and RGK Foundation. For more information, please visit us online at www.als.net.

About Anida Pharma
Anida Pharma, Inc. is a biopharmaceutical company developing novel first-in-class therapies to treat amyotrophic lateral sclerosis (ALS; Lou Gehrig disease), Parkinson's disease, other central nervous system disorders, and hearing loss. Our therapeutic concept is based on activating the body's own homeostatic mechanisms to regulate inflammation, prevent cell death and stimulate tissue repair. Visit our website: www.anidapharma.com to learn more.

Media Contacts:
Mari Sullivan, ALS TDI, 617-441-7220, msullivan@als.net
Per Gjorstrup, Anida Pharma, 617-331-5033, pgjorstrup@anidapharma.com


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
3. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
6. Aperture Health, Inc. focuses in on IV Therapy Value Creation and the Merger and Acquisition Activities in the Home Infusion Therapy Sector.
7. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
8. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
9. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
10. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
11. The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... total revenues of $39.8 million for the second quarter ... of $24.5 million for the second quarter of 2013. ... sold on May 30, 2014, has been accounted for ... been excluded from continuing operations for all periods. ...
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
(Date:7/29/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... specific pathogens that cause serious infections and diseases, announced ... in the Company,s stock, the NYSE MKT (the "Exchange") ... practice. The Company stated that its policy is not ... Synthetic Biologics, Inc. Synthetic Biologics, Inc. (NYSE ...
Breaking Medicine Technology:Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... diagnosisTAMPA, Fla., May 14 Moffitt Cancer ... have signed a license agreement on phospholipid ... been granted exclusive worldwide rights to Moffitt,s interests in ... maintenance fees, and royalties on sales. Moffitt and Frantz ...
... indicate statistically significant improvement in ACR20 responses over ... MEDX ) today announced that the ... active rheumatoid arthritis (RA) receiving methotrexate successfully met ... recently completed 70-patient multi-center, randomized, double-blind, placebo-controlled Phase ...
Cached Medicine Technology:Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC 2Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 2Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 3Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 4
(Date:7/30/2014)... 2014 According to the American Cancer Society, ... in the United States in 2014. (1) NTC ... the mortgage and financial industry, has long been a proponent ... and the company has further demonstrated its commitment by participating ... & Tarpon Springs event to increase awareness and fundraising efforts ...
(Date:7/30/2014)... 30, 2014 A formal complaint ... Office against the maker of the dialysis products ... Medical Care defrauded the state, its residents, physicians ... dialysates, before they were recalled in 2012. There ... these products pending in the U.S. District Court, ...
(Date:7/30/2014)... July 29, 2014 (HealthDay News) -- A simple blood ... spina bifida, new research finds. The test would ... in a pregnant women,s red blood cells. The findings from ... -- could help doctors predict the risk of serious birth ... to the proper development of a growing fetus. In ...
(Date:7/30/2014)... 30, 2014 (HealthDay News) -- ,Middle-aged adults with a ... likely as others to develop severe memory problems later ... British researchers said their findings could help doctors identify ... from help for problem drinking. "We already know ... of current alcohol consumption -- that understanding is based ...
(Date:7/30/2014)... Loffler Companies, the leading business technology and services ... new production printing machines from Konica Minolta and Canon ... better. , With blazing 100 page-per-minute output speed in ... press raises the bar in digital productivity, saves space ... costs with simple operation and powerful in-line finishing. The ...
Breaking Medicine News(10 mins):Health News:NTC Takes Action Against Cancer With 5th Consecutive Relay For Life of Palm Harbor & Tarpon Springs, Raises Over $12,000 for Cancer Research 2Health News:NTC Takes Action Against Cancer With 5th Consecutive Relay For Life of Palm Harbor & Tarpon Springs, Raises Over $12,000 for Cancer Research 3Health News:NTC Takes Action Against Cancer With 5th Consecutive Relay For Life of Palm Harbor & Tarpon Springs, Raises Over $12,000 for Cancer Research 4Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 2Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 3Health News:Blood Test Might Help Prevent Certain Birth Defects 2Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2Health News:Loffler Companies Introduces New Konica Minolta bizhub PRESS C1085/C1100 and Canon imagePRESS C800/C700 Devices 2Health News:Loffler Companies Introduces New Konica Minolta bizhub PRESS C1085/C1100 and Canon imagePRESS C800/C700 Devices 3
... Research Collaborative for Health, both in Ann Arbor, have ... disparities in access to liver transplantation among racial and ... of Liver Transplantation , a journal published by ... Study of Liver Diseases (AASLD). Organ allocation in ...
... Aug. 19 (HealthDay News)-- There were no smiles on the faces ... waiting on line for help from the Oregon Employment Department were ... lecture from a middle-aged woman, who leaned in close and whispered ... a lot of unhappy, stressed people here." At rows of ...
... ARBOR, Mich. A team of University of Michigan scientists ... lifespan of roundworms. Scientists who study aging have long known ... the goal is to find less drastic ways to achieve ... promising early evidence that scientists may succeed at finding targets ...
... Reporter , WEDNESDAY, Aug. 18 (HealthDay News) -- Quitting ... many headache-prone teens ease their suffering, new research suggests. ... between those three lifestyle factors and recurrent headaches among ... number of headaches teens get and forestall headaches for ...
... more than 1,800 years reduced the gastrointestinal side effects ... of the cancer treatment, Yale University researchers report. ... herbs, called PHY906, and is based on a herbal ... nausea, vomiting and diarrhea. The study, published August 18 ...
... transplantation (HCT) cures many blood diseases, two-thirds of long-term ... the procedure, according to a recent study published ... the American Society of Hematology. Overall, these patients were ... a severe or life-threatening health condition, such as cardiovascular, ...
Cached Medicine News:Health News:Hispanics and Asians less likely to receive liver transplants 2Health News:Hispanics and Asians less likely to receive liver transplants 3Health News:Jobless and Stressed but Holding Out Hope 2Health News:Discovery may aid search for anti-aging drugs 2Health News:Discovery may aid search for anti-aging drugs 3Health News:Bad Habits Tied to Recurrent Headaches in Teens 2Health News:Bad Habits Tied to Recurrent Headaches in Teens 3Health News:Chronic health conditions common for stem cell transplant survivors 2Health News:Chronic health conditions common for stem cell transplant survivors 3
... benefits of fibre bronchoscopy: The HF-compatible V ... all other fibre bronchoscopes are measured., ... PENTAX, including the FB-19TV, FB-18V and FB-15V ... and the pediatric FB-8V, offer much better ...
... therapeutic fiberoptic bronchoscopes offers ... channel with a slim ... channel allows for improved ... of cytology brushes. The ...
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
Medicine Products: